Ethyl vanillateCAS# 617-05-0 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 617-05-0 | SDF | Download SDF |
| PubChem ID | 12038 | Appearance | Cryst. |
| Formula | C10H12O7 | M.Wt | 244.2 |
| Type of Compound | Phenols | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | ethyl 4-hydroxy-3-methoxybenzoate | ||
| SMILES | CCOC(=O)C1=CC(=C(C=C1)O)OC | ||
| Standard InChIKey | MWAYRGBWOVHDDZ-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C10H12O4/c1-3-14-10(12)7-4-5-8(11)9(6-7)13-2/h4-6,11H,3H2,1-2H3 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. Ethyl vanillate may be useful in selected cases of disseminated coccidioidomycosis. 2. Ethyl vanillate is a strong hydrogen peroxide scavenger, it may serve as an adjunct therapy for the treatment of vitiligo, although changes in pigmentation are mild clinically. |
| Targets | Antifection |
Ethyl vanillate Dilution Calculator
Ethyl vanillate Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 4.095 mL | 20.475 mL | 40.95 mL | 81.9001 mL | 102.3751 mL |
| 5 mM | 0.819 mL | 4.095 mL | 8.19 mL | 16.38 mL | 20.475 mL |
| 10 mM | 0.4095 mL | 2.0475 mL | 4.095 mL | 8.19 mL | 10.2375 mL |
| 50 mM | 0.0819 mL | 0.4095 mL | 0.819 mL | 1.638 mL | 2.0475 mL |
| 100 mM | 0.041 mL | 0.2048 mL | 0.4095 mL | 0.819 mL | 1.0238 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- OMDM-2
Catalog No.:BCC5814
CAS No.:616884-63-0
- H-Alaninol
Catalog No.:BCC2731
CAS No.:6168-72-5
- 3-(Dimethylsulfonio)-N,N,N-trimethylpropanaminium(2+)
Catalog No.:BCN1397
CAS No.:61672-51-3
- Trimethyl[3-(methylthio)propyl]ammonium(1+)
Catalog No.:BCN1398
CAS No.:61672-50-2
- Neridienone B
Catalog No.:BCN4143
CAS No.:61671-56-5
- 11-Methoxyuncarine C
Catalog No.:BCN4142
CAS No.:61665-08-5
- Furomollugin
Catalog No.:BCN4141
CAS No.:61658-41-1
- MK 212 hydrochloride
Catalog No.:BCC6856
CAS No.:61655-58-1
- Propargyl p-toluenesulfonate
Catalog No.:BCN2266
CAS No.:6165-76-0
- Propargyl benzenesulfonate
Catalog No.:BCN2247
CAS No.:6165-75-9
- Protopine hydrochloride
Catalog No.:BCN5345
CAS No.:6164-47-2
- Amfenac Sodium Monohydrate
Catalog No.:BCC4620
CAS No.:61618-27-7
- 2-Hydroxy-1-methoxyanthraquinone
Catalog No.:BCN3091
CAS No.:6170-06-5
- 2-Chloro-1,4-phenylenediamine sulfate
Catalog No.:BCN8435
CAS No.:61702-44-1
- W-5 hydrochloride
Catalog No.:BCC6621
CAS No.:61714-25-8
- W-7 hydrochloride
Catalog No.:BCC6622
CAS No.:61714-27-0
- Fluvoxamine maleate
Catalog No.:BCC1215
CAS No.:61718-82-9
- Methyl 2-(5-acetyl-2,3-dihydrobenzofuran-2-yl)propenoate
Catalog No.:BCN1396
CAS No.:617722-55-1
- Methyl 2-(6-acetyl-5-hydroxy-2,3-dihydrobenzofuran-2-yl)propenoate
Catalog No.:BCN1395
CAS No.:617722-56-2
- 5-O-Methylnaringenin
Catalog No.:BCN4144
CAS No.:61775-19-7
- Ethyl 3,4,5-trimethoxybenzoate
Catalog No.:BCN3973
CAS No.:6178-44-5
- Trans-Melilotoside
Catalog No.:BCC8364
CAS No.:618-67-7
- Oxaliplatin
Catalog No.:BCC3932
CAS No.:61825-94-3
- Sipeimine
Catalog No.:BCN1201
CAS No.:61825-98-7
Evaluation of the Efficacy of Topical Ethyl Vanillate in Enhancing the Effect of Narrow Band Ultraviolet B against Vitiligo: A Double Blind Randomized, Placebo-Controlled Clinical Trial.[Pubmed:26538775]
Iran J Med Sci. 2015 Nov;40(6):478-84.
BACKGROUND: Vitiligo is an acquired disease of skin that presents with depigmented patches due to lack of melanocytes in the epidermis. Accumulation of toxic free radicals like hydrogen peroxide in the epidermis may be responsible for melanocytes death. Since Ethyl vanillate (vanillic acid ethyl ester) is a strong hydrogen peroxide scavenger, it may be effective against vitiligo. This study was carried out to evaluate the effect of Ethyl vanillate cream on vitiligo patients receiving phototherapy. METHODS: A double-blind placebo-controlled clinical trial using Ethyl vanillate cream 20% was performed on 30 cases of generalized stable vitiligo (randomly selected) who were receiving phototherapy in the outpatient clinic of Faghihi Hospital (Shiraz, Iran). The patients randomly applied Ethyl vanillate on an assigned lesion (left or right side of the body) and placebo on the opposite side lesion (almost the same size and location) twice a day for 3 months, while receiving a narrow band ultraviolet B (NB-UVB) 2-3 times weekly. Photos were taken at the beginning of the trial and at the end of 4(th), 8(th), and 12(th) weeks. Then, images were compared with the photos from the beginning of the trial based on VASI score. RESULTS: There was a significant change in pigmentation after applying Ethyl vanillate compared with baseline in medication side (P=0.002), but no significant change in placebo side (P=0.066). Additionally, there was a significant difference between medication and placebo sides in pigmentation (P=0.005). CONCLUSION: Ethyl vanillate may serve as an adjunct therapy for the treatment of vitiligo, although changes in pigmentation are mild clinically.
Disseminated coccidioidomycosis; treatment with ethyl vanillate; a preliminary report.[Pubmed:13150209]
Calif Med. 1954 May;80(5):349-56.
Ethyl vanillate, previously reported to be useful in the treatment of disseminated histoplasmosis, was administered to eight patients with disseminated coccidioidomycosis. Therapeutically effective concentrations of Ethyl vanillate were obtained in only three patients, but, in them, the disease was apparently arrested. Failures occurred with patients who were too ill to tolerate the large amounts of Ethyl vanillate required to attain a therapeutic concentration in the blood. The principal difficulties of administering Ethyl vanillate are (a) the large doses required and (b) the lack of a parenterally administrable form of the drug. Ethyl vanillate, although not universally applicable, may be useful in selected cases of disseminated coccidioidomycosis and should be given further trial.
